PIK3CA alterations and benefit with neratinib: Analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

  1. Chia, S.K.L.
  2. Martin, M.
  3. Holmes, F.A.
  4. Ejlertsen, B.
  5. Delaloge, S.
  6. Moy, B.
  7. Iwata, H.
  8. Von Minckwitz, G.
  9. Mansi, J.
  10. Barrios, C.H.
  11. Gnant, M.
  12. Tomašević, Z.
  13. Denduluri, N.
  14. Šeparović, R.
  15. Kim, S.-B.
  16. Jakobsen, E.H.
  17. Harvey, V.
  18. Robert, N.
  19. Smith, J.
  20. Harker, G.
  21. Zhang, B.
  22. Eli, L.D.
  23. Ye, Y.
  24. Lalani, A.S.
  25. Buyse, M.
  26. Chan, A.
  27. Show all authors +
Journal:
Breast Cancer Research

ISSN: 1465-542X,  1465-5411

Year of publication: 2019

Volume: 21

Issue: 1

Type: Article

DOI: 10.1186/S13058-019-1115-2 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus